About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, December 8th, 2014

The QualityStocks
Daily Stock List


Terra Tech Corp. (TRTC)

SmallCapVoice, Market Authority, Penny Stocks24, Penny Stock, and Center Stage Stocks reported earlier on Terra Tech Corp. (TRTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Terra Tech Corp., via its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. Terra Tech integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. The Company works closely with expert horticulturists, engineers, as well as plant scientists to develop and manufacture advanced proprietary products for the emerging urban agricultural industry and individual hobbyists. The Company operates in two distinct markets. One is Commercial Agriculture; the other is Retail Agriculture. Terra Tech has its corporate office in Irvine, California.
Regarding Commercial Agriculture, Terra Tech works with customers to help design, develop, and manufacture cultivation systems that maximize space and reduce energy costs. The Company offers rooftop/vertical hydroponic and aeroponic systems to custom designed greenhouse management systems.

Regarding Retail Agriculture, Terra Tech, through GrowOp Technology, designs and manufactures an advanced and affordable line of horticulture equipment. GrowOp Technology operates out of its warehouse facility in Oakland, California.

In addition Terra Tech concentrates on medical cannabis cultivation technology. The Company’s products include Commercial Hydroponic and Aeroponic Systems with 'ADS' Automated Dosing Systems; Digital Atmospheric Controllers: Lighting, Humidity, C02 and more, and Commercial Greenhouse Manufacturing.

By way of its wholly-owned subsidiary Edible Garden, Terra Tech cultivates a premier brand of local and sustainably grown hydroponic produce. This produce sells through leading grocery stores throughout Massachusetts, New Hampshire, New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania, Maine, Indiana, and Ohio.

Terra Tech announced this past August that its subsidiaries MediFarm, MediFarm I and MediFarm II submitted applications to operate Medical Marijuana Enterprises (MME) to the state of Nevada. Terra Tech has already received a special use permit for a cultivation and production facility in Clark County, Nevada. It also submitted its applications for a special use permit and compliance permit to the City of Las Vegas, Nevada.

Recently, the Company announced that it placed its supercritical CO2 cannabinoid extraction facility into production. Terra Tech announced that it completed testing and formulating compounds at its cannabinoid extraction facility in Northern California. The Company is currently moving into production. It will be producing an assortment of oils, waxes, and other mediums of concentrated cannabinoids

Last week, Terra Tech provided an update on its Nevada Medical Cannabis efforts. It recently announced that MediFarm, MediFarm I, and MediFarm II, have all received provisional certificates from the State of Nevada in each local jurisdiction where they applied for a Medical Marijuana Establishment license. Together, these subsidiaries were issued 4 Dispensary provisional certificates, 2 Cultivation provisional certificates, as well as 2 Production provisional certificates spanning Northern and Southern Nevada.

Terra Tech Corp. (TRTC), closed Monday's trading session at $0.33, even for the day, on 892,047 volume with 257 trades. The average volume for the last 60 days is 1,863,363 and the stock's 52-week low/high is $0.079/$1.42.

Cannabis Kinetics Corp. (CANK)

Today we are highlighting Cannabis Kinetics Corp. (CANK), here at the QualityStocks Daily Newsletter.

OTC Bulletin Board-listed Cannabis Kinetics Corp. is an emerging fully integrated cannabis management business. It consists of four operating divisions: HBH Industries Incorporated; Monarch America, Inc.; REM International, and R.E.M. Beverages. The Company has targeted different opportunities in the Colorado marijuana marketplace. Cannabis Kinetics is based in Westminster, Colorado.

Cannabis Kinetics is focusing on the management of recreational and medical marijuana retail dispensaries, the management of licensed marijuana cultivation facilities, the production and distribution of hemp and marijuana infused food & beverage, and ancillary products. In addition, the Company will provide management of retail and wholesale operations for grow stores.

Additionally, Cannabis Kinetics’ plan is to pursue additional business opportunities. It will pursue these within manufacturing, equipment leasing, real estate, product licensing and distribution, along with other strategic acquisitions.

Cannabis Kinetics’ REM International division provides on-the-ground worldwide sourcing, proprietary product development, manufacturing, and logistics solutions for Monarch's proposed grow store outlets and future retail (dispensary) facilities. Moreover, R.E.M. Beverages was formed to design, develop and manufacture a proprietary line of marijuana infused beverage products. These include energy drinks, non-alcoholic beers, as well as coffee-infused beverages.

Its HBH Industries is a wholly-owned subsidiary. HBH is the direct management company for Monarch America, REM International, and R.E.M Beverage. Monarch America established to provide safety, consistency, quality, and brand awareness to the public, by way of regulatory allowed licensing, branding and lease agreement contracts with HBH Industries.

Monarch's central capability will be to sell Monarch branded marijuana, and manage and supply medical and recreational retail outlets (dispensaries). Furthermore, its central capability will be to develop and sell a proprietary line of food and beverage, personal care, soil amendment, and marijuana cultivation and personal use accessory products under the brand name and trademark MONARCH™.

Recently, Cannabis Kinetics announced an agreement to supply Monarch brand Coco Coir growing medium to an established Colorado based retail and grow facility management company with numerous locations. Cannabis Kinetics expects it will supply between 1,000 and 1,500 bags of Monarch Coco Coir monthly on an on-going basis to the purchaser.

Last week, Cannabis Kinetics announced that its Board of Directors approved motions to change the name of the Company to Monarch America, Inc. and execute a 3-for-1 forward split of its common stock. Furthermore, last week, Cannabis Kinetics announced that it submitted the required documentation with the state of Nevada to form Monarch America, Inc., the new wholly-owned subsidiary of the Company. The new subsidiary has been formed solely for the purpose of merging with and into Cannabis Kinetics to effect a previously proposed Company name change to Monarch America, Inc.

Cannabis Kinetics Corp. (CANK), closed Monday's trading session at $1.17, up 1.74%, on 136,804 volume with 123 trades. The average volume for the last 60 days is 71,040 and the stock's 52-week low/high is $0.60/$6.00.

Aethlon Medical, Inc. (AEMD)

PennyStockRumors, PricelessPennyStocks, Actual Gains, Clutch Investments, AllPennyStocks, Pennybuster, TopPennyStockMovers, SmallCapStockPlays, and StockBlogs reported on Aethlon Medical, Inc. (AEMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aethlon Medical, Inc.'s mission is to create novel medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Its Aethlon ADAPT™ System (Adaptive Dialysis-Like Affinity Platform Technology) is a revenue-stage technology platform. The ADAPT™ system provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. Aethlon Medical is based in San Diego, California. The Company’s shares trade on the OTC Markets’ OTCQB.

Aethlon Medical announced, in September 2013, the formal launch of Exosome Sciences, Inc. (ESI). This is its majority-owned subsidiary established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease, as well as other life-threatening conditions.

The Aethlon ADAPT™ System is a medical device platform that joins single or multiple affinity drug agents with advanced plasma membrane technology. This is to create therapeutic filtration devices, which selectively remove harmful particles from the entire circulatory system without the loss of essential blood components.

The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer. The Company’s Aethlon Hemopurifier® is a first-in-class medical device with broad spectrum capabilities against viral pathogens. These include the human immunodeficiency virus (HIV), hepatitis C virus (HCV), and many bioterror and pandemic threats.

Additionally, Aethlon Medical has its ELLSA™ Exosome Assay. This is an enzyme-linked lectin-specific assay that has demonstrated the ability to identify and quantify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and all forms of cancer tested so far.

The Company’s pipeline also includes a medical device undergoing development under a five-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers (DARPA Sepsis Program). Aethlon also has its HER2osome™. It provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer.

Last week, Aethlon Medical reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India.  Aethlon is presently preparing to launch its first human clinical studies in the U.S. In this study, HCV-infected individuals were enrolled to receive three six-hour Hemopurifier® treatments during the first three days of a 48-week peginterferon+ribavirin (PR) treatment regimen.  The study took place under the leadership of Dr. Vijay Kher at the Medanta Medicity. This is a multi-specialty medical institute founded to be a premier center for medical tourism in India.

Aethlon Medical, Inc. (AEMD), closed Monday's trading session at $0.2601, down 11.83%, on 7,120,829 volume with 869 trades. The average volume for the last 60 days is 5,727,590 and the stock's 52-week low/high is $0.1025/$0.72.

SmartMetric, Inc. (SMME)

Wall Street Resources and SmallCapFinancialWire reported on SmartMetric, Inc. (SMME), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed SmartMetric, Inc. has added a fingerprint scanner built inside EMV payment credit and debit chip cards. Therefore, this creates a second layer biometric authentication protection in defending against card fraud. The Company is now marketing its technology to card issuing financial institutions globally. SmartMetric has its headquarters In Las Vegas, Nevada. Its engineering office is in Tel-Aviv Israel. The Company’s development office is in Argentina and it has an office in Melbourne, Australia for Asia Pacific markets.

The SmartMetric developed in card biometric identification and activation system employs a SmartMetric developed ultra-miniature fingerprint reader. This reader stores and reads an individual’s fingerprint. The card user's fingerprint is stored inside the card. It never travels across networks or is never stored on a central computer. It cannot be hacked by number and password generators commonly used by today's card fraudsters - unlike a PIN or password.

SmartMetric has created a security solution replacing the reliance on card PIN's with a person’s fingerprint.  Built inside the payments card is a totally functional fingerprint reader. Upon a customer touching the sensor, it reads the person’s fingerprint and subsequently, upon a match, activates the cards EMV chip. If there is no match there is no card activation.  It is user-friendly and works with existing EMVE systems.

The SmartMetric Biometric Vault Card has an internal processor and its own computer operating system for standalone on-card processing.  It comes standard with 8GB of memory and can release cards with up to 128 GB of memory. Within the card is a miniature power management system, which handles the re-charging of the cards internal battery.

With the biometric protected vault card, an individual using their fingerprint to lock and unlock their own biometric protected stored value card provides safety, discrete portability, and a real time main street payments card. The card will work on standard ATM's worldwide. SmartMetric is preparing to start mass production in Q1 2015 with major financial institutions worldwide already expressing interest in using the Company’s biometric security solution.

The Company also offers its MedicalKeyring™. It is a product that uses the world's first smallest miniature fingerprint scanner, engineered and developed by SmartMetric. This enables a person to carry their complete medical files with them. All the files are protected by the file owner's biometric fingerprint.

SmartMetric, Inc. (SMME), closed Monday's trading session at $0.065, up 22.64%, on 104,678 volume with 13 trades. The average volume for the last 60 days is 96,534 and the stock's 52-week low/high is $0.035/$0.245.

TransAKT Ltd. (TAKD)

Today we are reporting on TransAKT Ltd. (TAKD), here at the QualityStocks Daily Newsletter.

TransAKT Ltd. is a manufacturer of highly innovative agricultural equipment used to grow a large array of vegetables and fruit using simulated sunlight from LED lamps in a proprietary hydroponic system. Furthermore, the Company is an international distributor of LED lighting products centered on serving the fastest growing market of commercial, hospitality, and outdoor lighting. The Company's global corporate management team is based in Las Vegas, Nevada; Calgary, Alberta; and Taipei, Taiwan.

TransAKT’ dedication is to helping business owners in protecting the environment by way of superior energy efficiency - replacing current non-energy-efficient light sources with energy-efficient light sources.

TransAKT’s wholly-owned subsidiary is Vegfab. Vegfab’s product line includes systems for commercial production and a home growing system that enables families to grow safe and clean fruit and vegetables in their homes. Vegfab Agriculture Technology Co., Ltd. was established in 2010 by a team of ecologically minded semiconductor specialists knowledgeable about LED materials.

TransAKT is concentrating on eliminating the use of chemical fertilizers and pesticides through the use of the latest hydroponic agricultural technology and pure nutrients. The nutrient solutions used in production with the Company’s hydroponic systems leave no heavy metal and chemical residues.

The Company's vegetable production factory in Yangmei City, Taiwan is the only mass production facility for vegetables in Taiwan. This facility uses innovative technology to produce exceptional yields from a very small space. Production is extremely efficient via the use of simulated sunlight from LED lamps, up to 85 percent automated.

Recently, TransAKT announced that it entered into a partnership with Taiwan Flora Seed International Co. Ltd. Taiwan Flora is an agricultural technology solution provider. It supplies finished products, training, as well as assistance to customers to setup greenhouse facilities and to successfully market their products.

Mr. James Wu, TransAKT Chairman, said, "We are committed to providing the safest and cleanest fruits and vegetables through the use of our latest hydroponic agricultural technology. Through our partnership with Taiwan Flora we're excited to be able to offer premium quality orchids and flowers all over the world. I expect that our combined expertise in agricultural technology will ensure that TransAKT is profitable in 2015."

TransAKT Ltd. (TAKD), closed Monday's trading session at $0.06, even for the day, on 115,000 volume with 10 trades. The average volume for the last 60 days is 66,610 and the stock's 52-week low/high is $0.015/$0.14.

Changing Technologies, Inc. (CHGT)

TheMicrocapNews reported earlier on Changing Technologies, Inc. (CHGT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Changing Technologies, Inc. is working to be at the vanguard of the next generation of consumer-based technology. The OTC Bulletin Board listed Company continues to investigate opportunities in the fast-growing 3D printing industry. A developing technology enterprise, it focuses on developing innovative concepts to bring to consumers. It developed its goal from the need to explore and offer applications principally centering on improving personal and business productivity and health and fitness monitoring.  Changing Technologies has its headquarters in Houston, Texas.

The Company helps its clients’ develop applications (apps). Changing Technologies helps guide them through its unique “Path Practice” process. This is its tested methodology of helping clients visualize the customer experience, data interactivity, and results expectations.

Changing Technologies recently created a new subsidiary called 6th Dimension Technologies. This subsidiary is to pursue additional growth areas and market needs in the growing 3D printing sector.  6th Dimension Technologies’ emphasis is on the first retail micro-manufacturing kiosk. 6th Dimension Technologies is growing its position in the multi-billion dollar 3D printing market.

6th Dimension has its state-of-the art, on-demand retail model for 3D printing at www.6D3D.com. The site will feature a wide array of 3D printable projects created by design engineers. These projects include arts and crafts, jewelry, and more.

Last week, Changing Technologies’ (CHGT) Chief Executive Officer, Omar T. Durham said that wearable tech – advanced technology worn on the body and weaved into everyday life – as well as3D printing, a technology destined to transform major industries globally, are a cutting-edge combination with unlimited possibilities.

Omar T. Durham said, “With Apple set to launch its much-anticipated wearable tech watch in early 2015 and 3D printing quickly working its way into the mainstream, these two cutting-edge tech niches are still in their infancy but imagine the growth if you combined them. The possibilities would be endless. Together, 3D printing and wearable technology – 3D printed wearable tech – is a combination that could easily elevate a market past its projected 2018 valuation of $5.8 billion. CHGT is excited to see where 3D printing can take a niche like wearable technology, which is on the precipice of massive growth.”

Changing Technologies, Inc. (CHGT), closed Monday's trading session at $0.40, down 11.11%, on 148,619 volume with 60 trades. The average volume for the last 60 days is 140,670 and the stock's 52-week low/high is $0.43/$5.20.

Ocata Therapeutics, Inc. (OCAT)

Today we choose to report on Ocata Therapeutics, Inc. (OCAT), here at the QualityStocks Daily Newsletter.

A clinical stage biotechnology company, Ocata Therapeutics, Inc. is concentrating on the development and commercialization of regenerative ophthalmology therapeutics. The Company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, as well as myopic macular degeneration. Ocata Therapeutics shares trade on the OTC Markets’ OTCQB. The Company has its corporate headquarters in Marlborough, Massachusetts.

Ocata Therapeutics’ principal research and development (R&D) and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Its intellectual property (IP) portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – as well as other cell therapy research programs.

The Company’s lead clinical program involves RPE Cell Therapy for treating macular degeneration. In addition, it is developing a Photoreceptor Progenitor Cell Therapy. It intends for this to be used for treating a broad assortment of retinal degenerations in diseases where photoreceptors malfunction and/or die.

Ocata’s Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells and forms new ganglion nerve cells. Furthermore, Ocata is developing therapeutic platforms utilizing Corneal Endothelial Cells for use in treating corneal blindness.

Last month, Ocata Therapeutics announced that it was granted Advanced Therapy Medicinal Product (ATMP) designation for its RPE therapy for macular degeneration. This designation is an essential step in allowing companies to commercialize products effectively across the European Union (EU).

Dr. Eddy Anglade, Ocata Therapeutics’ Chief Medical Officer, said: “We are pleased to receive ATMP status from the EMA. We view this as an important step to further enable the development of our novel biological therapy in the EU with the aim of seeking marketing authorization approval. Additionally, we interpret this as a favorable indication for how the European regulators view our therapy.”

Ocata Therapeutics, Inc. (OCAT), closed Monday's trading session at $6.82, up 2.10%, on 222,887 volume with 312 trades. The average volume for the last 60 days is 31,862 and the stock's 52-week low/high is $4.95/$12.73.


The QualityStocks
Company Corner


Nhale, Inc. (NHLE)

The QualityStocks Daily Newsletter would like to spotlight Nhale, Inc. (NHLE). Today, Nhale, Inc. closed trading at $0.54, off by 6.90%, on 111,771 volume with 41 trades. The stock’s average daily volume over the past 60 days is 40,729, and its 52-week low/high is $0.14/$1.33.

Nhale, Inc. today announced it has delivered a letter of intent (LOI) to a profitable outdoor marijuana grower in Washington state. The grower is a licensed producer helping supply an exploding demand for legal pot in that state since retail recreational marijuana stores opened for business this July.

Nhale, Inc. (NHLE) develops and sells leading-edge technology in alignment with its mission to become a recognized, premier innovator in cannabis cultivation, dispensaries, testing and scientific products. Nhale explores innovations that will position the company on the front lines of the marijuana revolution.

Nhale is currently aggressively focused on grow operations in states where cannabis is legal, or soon to be legal, such as Oregon, Alaska and Florida. As an increasing number of states move towards legalization for medical or recreational use, growers are positioned to benefit from economies of scale due to escalating demand. Focusing on candidates in the cultivation space, Nhale is poised grow into a successful, sustainable enterprise through product or company acquisition in this explosive space.

Growpod, Nhale’s self-contained grow environment technology, is one of the company’s products and an entry point into the promising cultivation technology space. Growpod uses “controlled environment agriculture” to optimize plant development, plant quality and production efficiency in all climates and seasons.

Nhale believes innovation produces profitability, especially in growth-stage organizations entering emerging industries. This belief guides Nhale’s strong commitment to develop and commercialize cutting-edge consumer-oriented products primed for rapid commercialization. The company has identified strategic industry partnerships to support this growth objective and to secure an increasing footprint in the booming marijuana market. Disclaimer

Nhale, Inc. Company Blog

Nhale, Inc. News:

Nhale (NHLE) Submits LOI to Washington Marijuana Producer Following Financial Review

Nhale (NHLE) Working to Secure $10 Million in Financing

Marijuana Grow and Retail Operation Taps Nhale (NHLE) for Collaboration

Boreal Water Collection, Inc. (BRWC)

The QualityStocks Daily Newsletter would like to spotlight Boreal Water Collection, Inc. (BRWC). Today, Boreal Water Collection, Inc. closed trading at $0.0046, up 24.32%, on 336,988 volume with 7 trades. The stock’s average daily volume over the past 60 days is 933,200, and its 52-week low/high is $0.0032/$0.03.

Boreal Water Collection, Inc. (BRWC) is an established water bottler of premium private-labeled bottled water products tailored for each client’s particular need, be it publicity, promotion, marketing, internal use or a specific event. This emphasis on customization and quality has earned Boreal an impressive reputation, evidenced by its prestigious customer base of high-end beverage brands, retailer channels, high-end hotels and restaurant chains such as H&M, Mercedes, W Hotels, Dean & Deluca, Fred Water, Wat-aah, Saks Fifth Ave, Balance Water, NY Quin Hotel, Bouchon Bakery and Princeton University, just to name a few!

Located 90 miles north New York City, Boreal’s plant is only 17 miles from its well-protected source of natural spring water, a pristine and abundant spring source deep inside the heart of the Catskill Mountains. The spring’s exceptional geological and geographical features have created the perfect environment for Boreal’s low-mineral, sodium-free and well-balanced PH water. With exclusive exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.

Boreal offers a line of award-winning water products, including functional enhanced water, infused water, carbonated water, vitamins enhanced water, flavored still or sparkling, minerals enhanced water, oxygenated water, electrolyte water, distilled water, alkaline water, caffeinated water and natural spring water.

Accommodating this plentiful water supply and range of product offerings, Boreal has established a 75,000-square foot manufacturing facility. Boreal can process a full range of water and bottle types and has the most creative staff for all private labeling needs. The company offers fully integrated turnkey service, made-to-order labeling along with distinctive water bottles. In short, Boreal is a “Boutique Bottler” and is focusing on becoming the leader of this attractive niche of the growing multi-billion dollar bottled water industry. Disclaimer

Boreal Water Collection, Inc. Company Blog

Boreal Water Collection, Inc. News:

Boreal Water Collection to Exhibit at China's Largest Food Show

Boreal Water Collection Reports Continued Growth in the Third Quarter of 2014, Sales Increase by 14% While Profitability Rises by 57%

The Chatwal Hotel (NY) Agrees to Have Boreal Water Collection Produce Their Private Labeled Bottled Water

Ecrypt Technologies, Inc. (ECRY)

The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.505, up 18.82%, on 5,342,352 volume with 1,427 trades. The stock’s average daily volume over the past 60 days is 1,296,511 and its 52-week low/high is $0.09/$0.508.

Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.

Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.

The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.

Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer

Ecrypt Technologies, Inc. Blog

Ecrypt Technologies, Inc. News:

Microsoft CSO and Ecrypt CEO Share Inaugural Security Industry Award

Ecrypt's Market Alliance Member, Cicada Security Technology Inc., Announces the Launch of New Data Privacy Products

Ecrypt Technologies Secures Multi-Year Contract With Global High Tech Manufacturer

IFAN Financial, Inc. (IFAN)

The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.627, up 1.13%, on 1,623,003 volume with 609 trades. The stock’s average daily volume over the past 60 days is 321,782, and its 52-week low/high is $0.0114/$0.62.

IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.

Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.

Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.

IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer

IFAN Financial, Inc. Company Blog

IFAN Financial, Inc. News:

IFAN Financial, Inc. (IFAN) CEO Featured in Exclusive QualityStocks Interview

IFAN Financial, Inc. (IFAN) Announces Engagement of QualityStocks Investor Relations Services

IFAN Financial Acquires Mobile Payment Solutions Provider Mobicash America, Inc.

WordLogic Corp. (WLGC)

The QualityStocks Daily Newsletter would like to spotlight WordLogic Corp. (WLGC). Today, WordLogic Corp. closed trading at $0.0732, even for the day, on 27,215 volume with 5 trades. The stock’s average daily volume over the past 60 days is 52,625, and its 52-week low/high is $0.05/$0.26.

WordLogic Corp. (WLGC) leverages more than 10 years of advanced R&D to assume its position as a global leader in predictive text input technology. Backed by multiple patents and its predictive engine, WordLogic’s interface is revolutionizing the way individuals and businesses search and communicate on touch screen devices. Furthermore, WordLogic offers a range of licensing options of its technology and patent portfolio.

The company’s technology incorporates proprietary Gesturing™ and WordChunking™ features that accelerate typing speeds while reducing the effort needed for accuracy. This interface increased text input on mobile devices by five times, rapidly speeding communication via instant messaging, text messaging, captioning, email and information searching. The iKnowU® keyboard uses state-of-the-art patented technology that becomes more accurate with each use, constantly learning about the user’s style and preferences. Utilizing the WordChunking and Gesturing, iKnowU enables the user to chain together phrases and create whole sentences in a matter of seconds.

For the business realm, WordLogic has developed a unique cloud solution to fit the specific needs of multiple industry sectors, enabling enterprises to create a single cloud-based dictionary specific to the company’s realm of expertise or multiple dictionaries specific for individual specialties or departments. This cloud solution creates continuity for users across multiple devices, boosting accuracy and productivity. WordLogic Reach™ enables users to select and insert meeting plans, contact information, and calendar entries from other apps in the mobile device.

Frost & Sullivan recently recognized WordLogic as the recipient of the 2014 North American Enabling Technology Leadership Award for Predictive Keyboard Applications, saying, “WordLogic’s technically impressive product - WordLogic Predictive Engine and its associated products iKnowU® and Reach™ - offers key competitive advantages, such as market-leading word and phrase prediction capabilities, a context-aware advertising model; simpler integration, increased speed and accuracy; and reduced costs. Add to that the significant number of pending and issued patents and you can see how value a package of technology WordLogic has developed truly is.” Disclaimer

WordLogic Corp. Company Blog

WordLogic Corp. News:

WordLogic (OTCQB:WLGC) Announces that Apple Approves the Launch of an iOS8 Version of the iKnowU Keyboard

WordLogic the Sale of Exclusive Rights to Legal Enterprise Solutions to Private Equity Group

WordLogic Files Patent Infringement Lawsuit Against TouchType Ltd., Makers of SwiftKey

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $9.00, even for the day. The stock’s average daily volume over the past 60 days is 260, and its 52-week low/high is $5.20/$15.00.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder

VistaGen Receives Notice of Allowance for Canadian Patent, Further Expanding Stem Cell Technology Platform

VistaGen Announces Reverse Stock Split

Intercept Energy Services, Inc. (IESCF)

The QualityStocks Daily Newsletter would like to spotlight Intercept Energy Services, Inc. (IESCF). Today, Intercept Energy Services, Inc. closed trading at $0.023, even for the day. The stock’s average daily volume over the past 60 days is 5,953, and its 52-week low/high is $0.023/$0.075.

Intercept Energy Services, Inc. (IESCF) is an innovative Oilfield Services Firm (OFS) primarily focused on the deployment of its proprietary BIG HEAT frac water heating technology used by oil and gas exploration and production companies operating in Canada and the United States. The company also specializes in unconventional energy extraction and related services such as oil sands processing, oilfield equipment, and oilfield waste disposal and recovery of reusable products from waste.

The BIG HEAT is a patent pending propane-powered system that provides a superior heating method compared to traditional methods used by oil and gas companies and their fracking operations. Equipped with numerous safety shut-offs and little-to-no radiant heat emanating from an encased burner, the BIG HEAT virtually eliminates any possibility of on-site injuries or accidents associated with traditional water heating methods. The technology’s clean, complete and efficient burning capability makes it the most cost effective, safest and environmentally friendly frac water heating system available today.

Committed to providing innovative and efficient products to the oil and gas industry, Intercept Energy also offers an existing line of services and equipment designed that enhance safety, increase efficiency and result in lower costs. The latest addition to Intercept Energy’s portfolio is an Energy Superheater Unit, which is safe to operate, harmless to the well site infrastructure, and preserves environmental integrity.

Tapping into the lucrative $750 billion dollar oil and gas services industry, Intercept Energy has established a clearly defined business plan to deploy additional BIG HEAT units throughout Canada and the United States to follow the fastest route to generating new income, company value and growth. Intercept Energy has the exclusive use of and rights to operate the water heating units in Canada and further in certain areas in the United States. Intercept Energy trades on the OTCQB under ticker symbol “IESCF” and the Toronto Stock Exchange under the ticker symbol “IES.V”. Disclaimer

Intercept Energy Services, Inc. Company Blog

Intercept Energy Services, Inc. News:

Intercept Energy Services Reports Third Quarter 2014 Results and Engages Investor Relations Firm

Intercept Announces the Closing of the First Tranche of a Private Placement

Intercept Annual General Meeting Result


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters







Fast Money Alerts

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251